Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects
Acta Pharmaceutica Sinica B · 2025-08 · 15 (8) · 3852-3887
DOI: 10.1016/j.apsb.2025.06.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-08. Verfasst von Xueni Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, …. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 408 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science Fund for Distinguished Young Scholars, National Natural Science Foundation of China.
Abstract (Originalsprache)
Invasive fungal infections (IFIs) have become prominent global health threats, escalating the burden on public health systems. The increasing occurrence of invasive fungal infections is due primarily to the extensive application of chemotherapy, immunosuppressive therapies, and broad-spectrum antifungal agents. At present, therapeutic practices utilize multiple categories of antifungal agents, such as azoles, polyenes, echinocandins, and pyrimidine analogs. Nevertheless, the clinical effectiveness of these treatments is progressively weakened by the emergence of drug resistance, thereby substantially restricting their therapeutic utility. Consequently, there is an imperative need to expedite the discovery of novel antifungal agents. This review seeks to present an exhaustive synthesis of novel antifungal drugs and candidate agents that are either under current clinical investigation or anticipated to progress into clinical evaluation. These emerging compounds exhibit unique benefits concerning their modes of action, antimicrobial spectra, and pharmacokinetic characteristics, potentially leading to improved therapeutic outcomes relative to conventional antifungal regimens. It is anticipated that these novel therapeutic agents will furnish innovative treatment modalities and enhance clinical outcomes in managing invasive fungal infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of…
- Research Unit for Blindness Prevention of the Chinese Academy of Medical Sciences, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu 610054, China.
Förderung
- National Science Fund for Distinguished Young Scholars
- National Natural Science Foundation of China
Zitieren
APA
Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025). Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects. Acta Pharmaceutica Sinica B, 15(8), 3852-3887. https://doi.org/10.1016/j.apsb.2025.06.013
Vancouver
Lu X, Zhou J, Ming Y, Wang Y, He R, Li Y, et al. Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects. Acta Pharmaceutica Sinica B. 2025;15(8):3852-3887. doi:10.1016/j.apsb.2025.06.013
BibTeX
@article{Lu2025,
author = {Lu, Xueni and Zhou, Jianlin and Ming, Yi and Wang, Yuan and He, Ruirui and Li, Yangyang and Feng, Lingyun and Zeng, Bo and Du, Yanyun and Wang, Chenhui},
title = {Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects},
journal = {Acta Pharmaceutica Sinica B},
year = {2025},
volume = {15},
number = {8},
pages = {3852--3887},
doi = {10.1016/j.apsb.2025.06.013}
}
EUVIMED